Viagra compound may hold promise for treating fatal genetic disease: Animal studies and preliminary human data support the safety of sildenafil in Leigh syndrome, but the jury's out on whether it's effective.

This article focuses on research investigating the potential use of sildenafil, a phosphodiesterase type 5 inhibitor commonly known as Viagra, as a treatment for Leigh syndrome, a rare genetic disorder affecting mitochondrial function and causing severe neurological decline in children. Laboratory studies showed that sildenafil partially corrected cellular abnormalities in brain organoids derived from patients and modestly extended lifespan in animal models with different Leigh syndrome mutations. Preliminary data from a small group of patients with MT-ATP6 gene mutations suggest some symptomatic improvements, though experts caution that these findings are preliminary and require validation in larger clinical trials. A multi-country clinical trial involving 60 to 70 patients is planned to further assess sildenafil’s safety and efficacy in this ultrarare disease. [Extracted from the article]